45 results
8-K
EX-99.1
IMUX
Immunic Inc
14 Nov 23
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6:38am
of vidofludimus calcium or placebo.
July 2023: Hosted a virtual celiac disease expert roundtable to discuss the substantial unmet medical need for new
8-K
EX-99.1
IMUX
Immunic Inc
3 Aug 23
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:44am
found in prior trials,” concluded Dr. Vitt.
Second Quarter 2023 and Subsequent Highlights
July 2023: Hosted a virtual celiac disease expert
8-K
EX-99.1
IMUX
Immunic Inc
27 Apr 23
Departure of Directors or Certain Officers
6:40am
an extra-ordinary background spanning decades as a clinical expert in multiple sclerosis, clinical trialist who has overseen multiple successful pivotal
8-K
EX-99.1
a36dodsb1rz9 sh7kv
12 Jul 21
Other Events
7:00am
8-K
EX-99.1
at2szt f3p
1 Jul 21
Other Events
4:16pm
8-K
EX-10.1
nf1ospyqd 9c1idc1tgx
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
8-K
EX-10.1
wc591obsfkv8x0e1ec8
20 Apr 20
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.3
5q44vljf
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-3.2
v3yvte4d4rg i0193
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-10.4
ghrt02
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
424B3
ubjpzfpf6
19 Feb 19
Prospectus supplement
5:03pm
S-4/A
myj37509
14 Feb 19
Registration of securities issued in business combination transactions (amended)
9:02am